Response to Spangenberg and Koo, “Response to Schwarz C.W., et al. ‘Comparative 2-year drug survival of bimekizumab and brodalumab in second-line treatment of psoriasis”

Enriched record

Christopher Willy Schwarz, Nikolai Loft, Lone Skov

Abstract

No public abstract is available from the verified source records.

Authors

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

unpaywall

Confidence 95%

datacite

Confidence 0%

Referenced works

No local reference links have been materialized yet.

No local citing links have been materialized yet.

No reference metadata is available yet.

No additional external references are available.